Davide Voci

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Barco, Davide Voci, Ulrike Held et al. · The Lancet Haematology · 2022 · 59 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

Transient perivascular inflammation of the carotid artery (TIPIC) syndrome

Evy Micieli, Davide Voci, Nicola Mumoli et al. · VASA · 2022 · 27 citations

Medicine, Surgery, Pain Management +11

Deaths related to pulmonary embolism and cardiovascular events before and during the 2020 COVID-19 pandemic: An epidemiological analysis of data from an Italian high-risk area

Davide Voci, Ugo Fedeli, Ioannis T. Farmakis et al. · Thrombosis Research · 2022 · 25 citations · Full text

Medicine, Cardiology, Infectious Diseases +11

Enoxaparin for outpatients with COVID-19: 90-day results from the randomised, open-label, parallel-group, multinational, phase III OVID trial

Davide Voci, Andrea Götschi, Ulrike Held et al. · Thrombosis Research · 2022 · 20 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13

Mortality rate related to peripheral arterial disease: A retrospective analysis of epidemiological data (years 2008–2019)

Davide Voci, Ugo Fedeli, Luca Valerio et al. · Nutrition Metabolism and Cardiovascular Diseases · 2022 · 17 citations · Full text

Public Health, Biostatistics, Cardiology +17